LIPAC Oncology is a pharmaceutical company focused on advancing the development of new investigational therapies to treat intracavitary cancers. Its precision targeted liposome-bound nano-technology platform provides local delivery of taxane for the treatment of multiple tumor types. LiPax, its lead investigational candidate for the treatment of non-muscle invasive bladder cancer, is in Phase 2b development. The Company’s pipeline includes multiple orphan indications such as upper tract urothelial carcinoma, stage II/III ovarian cancer and mesothelioma.